Cerus opened lower at $2.09, compared with its previous close of $2.12. In the last trading session, the stock traded between $1.98 and $2.09. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Cerus is now worth
$ 26.47
Resulting in a loss of
$ 73.53 (73.53%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.19 (-8.73%)
Day High
$2.09
Day Low
$1.98
Day Open
$2.09
Prev Close
$2.12
Volume
14,32,167
1W Return
-20.07%
1M Return
-14.19%
3M Return
-24.41%
6M Return
-23.21%
1Y Return
17.27%
Fundamentals
Market Cap ($ Mn)
391
PE Ratio
-
PB Ratio
7.64
PEG Ratio
-
ROE
-26.71%
ROCE
-5.33%
EPS (TTM)
$0.00
Investment Returns
1 Week
-20.07%
1 Month
-14.19%
3 Months
-24.41%
6 Months
-23.21%
9 Months
-10.00%
Financials
Quarterly
All values in $ Mn
52.4
Jun 25
52.7
Sep 25
57.8
Dec 25
53.7
Mar 26
57.4
Jun 26
57.7
Sep 26
Updates
3Nov
Cerus Corp Q3FY26 Results: Product revenue up 10% to $57.7 million
Product revenue increased 10% YoY to $57.7 million, driven by North American demand. Adjusted EBITDA reached $5.7 million, marking the 10th consecutive positive quarter. IFC sales shifted 90% to kit form, supporting future gross margin expansion. Phase 3 REDIS trial met primary efficacy endpoint for red blood cell pathogen reduction.
10 days ago
3Nov
Cerus Corp files prospectus to sell up to $150M in securities
Cerus Corp filed a prospectus with the SEC. The filing allows the sale of up to $150 million in securities. Securities can be offered from time to time based on market conditions.
Primary efficacy endpoint met, demonstrating non-inferiority of INTERCEPT RBCs to conventional RBCs. Adjusted hemoglobin increment difference was -0.054 g/dL, within the prespecified non-inferiority margin. Related treatment-emergent adverse events occurred in 3.4% of INTERCEPT patients vs 2.5% in control. INTERCEPT-specific antibodies detected in 2.2% of treatment subjects without evidence of hemolysis.
10 days ago
20Oct
Cerus Corp sets Nov 2 for Q3FY26 results release
Cerus Corporation will release Q3 2026 financial results on November 2, 2026. Conference call scheduled for 4:30 pm ET following market close. Replay available on website until November 23, 2026.
24 days ago
31Jul
Cerus raises FY26 sales guidance to $229-231M as Q2 EPS meets estimates
Cerus raised its FY26 sales outlook to $229.000-$231.000 million following a Q2 report where EPS met estimates at $(0.01). Total revenue grew 5% to $63.3 million, with product revenue surging 10%, offsetting a 24% drop in government contracts and improved cost discipline.
3mo ago
17Jul
Cerus Corporation to release Q2 2026 results on July 30
Cerus Corporation is set to announce its Q2 2026 financial results on July 30, 2026, after market close. A conference call will follow at 4:30 P.M. ET to discuss the results and business outlook. A replay will be available until August 20, 2026.
